Oppenheimer Affirms Outperform Rating for Ventyx Biosciences
Nov 8, 2024
Ventyx Investment Portfolios
Ventyx Biosciences Faces Setback as Crohn's Disease Drug Candidate VTX958 Fails Phase 2 Trial
Jul 29, 2024